Literature DB >> 22910173

Prevalence of psoriasis in China: a population-based study in six cities.

Xiaolan Ding1, Tinglin Wang, Yiwei Shen, Xiaoyan Wang, Cheng Zhou, Shan Tian, Ying Liu, Guanghui Peng, June Zhou, Shuqi Xue, Renli Wang, Ying Tang, Xuemei Meng, Guangde Pei, Yunhua Bai, Qing Liu, Hang Li, Jianzhong Zhang.   

Abstract

BACKGROUND: Although psoriasis occurs worldwide, the prevalence varies considerably between different peoples and regions. In China, a questionnaire-based study was carried out in 1987 and the prevalence of psoriasis was found to be 0.12%. Since then, no large-scale, population-based study has been reported.
OBJECTIVES: To obtain the accurate figures for the prevalence of psoriasis in China.
METHODS: A population-based survey was conducted in 6 cities. The cluster sampling method was used to select communities in each city. The subjects were required to fill out self-reporting questionnaires during a face-to-face interview and also received physical examination by dermatologists.
RESULTS: 19,974 subjects were visited and 17,345 completed the questionnaires and received dermatological examination. 102 subjects (0.59%) were found to have psoriasis. After standardization, the prevalence of psoriasis was 0.47%. The prevalence of psoriasis in males and females was 0.54% and 0.44% respectively. 97.06% of the patients had psoriasis vulgaris. 28.43% of the patients reported a family history of psoriasis. 59.80% of patients experienced a negative influence on the quality of life.
CONCLUSIONS: This population-based and dermatologist-confirmed study showed that the prevalence of psoriasis in China is 0.47%, which is higher than that reported in 1987.

Entities:  

Mesh:

Year:  2012        PMID: 22910173     DOI: 10.1684/ejd.2012.1802

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  64 in total

1.  Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial.

Authors:  L Kemeny; M Amaya; P Cetkovska; N Rajatanavin; W-R Lee; A Szumski; L Marshall; E Y Mahgoub; E Aldinç
Journal:  BMC Dermatol       Date:  2015-05-21

Review 2.  Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis.

Authors:  Zeyu Chen; Yu Gong; Yuling Shi
Journal:  Clin Drug Investig       Date:  2017-10       Impact factor: 2.859

3.  MiR-126 correlates with increased disease severity and promotes keratinocytes proliferation and inflammation while suppresses cells' apoptosis in psoriasis.

Authors:  Shike Feng; Lin Wang; Wang Liu; Yan Zhong; Shijun Xu
Journal:  J Clin Lab Anal       Date:  2018-06-26       Impact factor: 2.352

4.  Combined effect of five single nucleotide polymorphisms related to IL23/Th17 pathway in the risk of psoriasis.

Authors:  Xianyong Yin; Hui Cheng; Ran Zhang; Xing Fan; Fusheng Zhou; Long Jiang; Xianfa Tang; Gang Chen; Xianbo Zuo; Xiaodong Zheng; Sen Yang; Xuejun Zhang
Journal:  Immunogenetics       Date:  2014-01-14       Impact factor: 2.846

5.  Health state utilities and subjective well-being among psoriasis vulgaris patients in mainland China.

Authors:  Liu Liu; Shunping Li; Yue Zhao; Jianglin Zhang; Gang Chen
Journal:  Qual Life Res       Date:  2018-02-28       Impact factor: 4.147

6.  Safety and Efficacy of Methotrexate for Chinese Adults With Psoriasis With and Without Psoriatic Arthritis.

Authors:  Kexiang Yan; Yuanjing Zhang; Ling Han; Qiong Huang; Zhenghua Zhang; Xu Fang; Zhizhong Zheng; Nikhil Yawalkar; Yuling Chang; Qun Zhang; Ling Jin; Danfeng Qian; Xueying Li; Mingshun Wu; Qiaohu Xu; Xuejun Zhang; Jinhua Xu
Journal:  JAMA Dermatol       Date:  2019-03-01       Impact factor: 10.282

7.  Interleukin-33 alleviates psoriatic inflammation by suppressing the T helper type 17 immune response.

Authors:  Zeyu Chen; Yifan Hu; Yu Gong; Xilin Zhang; Lian Cui; Rongfen Chen; Yingyuan Yu; Qian Yu; Youdong Chen; Hongyue Diao; Jia Chen; Yuanyuan Wang; Yuling Shi
Journal:  Immunology       Date:  2020-05-25       Impact factor: 7.397

8.  Common susceptibility variants are shared between schizophrenia and psoriasis in the Han Chinese population.

Authors:  Xianyong Yin; Nathan E Wineinger; Kai Wang; Weihua Yue; Nina Norgren; Ling Wang; Weiyi Yao; Xiaoyun Jiang; Bo Wu; Yong Cui; Changbing Shen; Hui Cheng; Fusheng Zhou; Gang Chen; Xianbo Zuo; Xiaodong Zheng; Xing Fan; Hongyan Wang; Lifang Wang; Jimmy Lee; Max Lam; E Shyong Tai; Zheng Zhang; Qiong Huang; Liangdan Sun; Jinhua Xu; Sen Yang; Kirk C Wilhelmsen; Jianjun Liu; Nicholas J Schork; Xuejun Zhang
Journal:  J Psychiatry Neurosci       Date:  2016-10       Impact factor: 6.186

Review 9.  A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.

Authors:  Yifan Hu; Zeyu Chen; Yu Gong; Yuling Shi
Journal:  Clin Drug Investig       Date:  2018-03       Impact factor: 2.859

10.  Seasonal Variation of Psoriasis and Its Impact in the Therapeutic Management: A Retrospective Study on Chinese Patients.

Authors:  Xuanwei Zheng; Qiaolin Wang; Yan Luo; Wenhua Lu; Liping Jin; Menglin Chen; Wu Zhu; Yehong Kuang
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.